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Abstract
Hemophilia A is an X-linked blood disorder that results in the inability to form proper
blood clots and may also cause spontaneous bleeding in the joints or muscles. This disorder
is caused by mutations in the F8 gene that attenuate or abolish the activity of its protein
product, factor VIII. Blood coagulation factor VIII (fVIII) is a glycoprotein that serves as
a cofactor for the serine protease factor IXa on the surface of activated platelets to form
the intrinsic tenase complex, which activates factor X during hemostasis to enable blood
clot formation. Previous studies have shown that the C-terminal (C2) domain of fVIII is
responsible for binding to phospholipids in platelet membranes. However, there are
conflicting models for its structural binding mechanism. Elucidating the mechanism of
factor VIII binding to phosphatidylserine-containing membranes in activated platelets is
essential in the understanding and progress towards improving current hemophilia A
therapeutics. Some mutations that occur in the C2 domain result in nonfunctional factor
VIII possibly due to its inability to bind platelet membranes and form the tenase complex.
This research helps to further describe this mechanism by analyzing the atomic interactions
between the C2 domain of factor VIII and phosphatidylserine membranes by X-ray
crystallography and biochemical assays. A 1.4 Å resolution X-ray crystal structure of the
porcine C2 domain of factor VIII in complex with O-phospho-L-serine (OPLS), a soluble
moiety of the headgroup of phosphatidylserine, revealed a favorable electrostatic
interaction between Arg2320 and OPLS, implying the importance of the universally
conserved arginine at residue 2320. Within the human hemophilia A population, two
mutations at that residue in fVIII, Arg2320Thr/Ser, are of interest due to the ability of
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these fVIII mutants to stay in circulation as non-functioning proteins. Characterizing these
mutants with phosphatidylserine membrane-binding enzyme-linked immunosorbent
assays (ELISAs), affinity pull-down assays, and intrinsic fluorescence has allowed for a
more comprehensive understanding of the binding mechanism of fVIII. Because the C1
domain of fVIII is structurally homologous to the C2 domain, we attempted to study two
naturally occurring mutations (Arg2163His and Arg2159His) in the C1 domain that likely
interact with phosphatidylserine-containing membranes. Arg2163His is a mutation located
in the same position structurally as Arg2320 in the C2 domain. However, we were unable
to purify these C1 mutants to a level suitable for biochemical studies. Furthermore,
phosphatidylserine lipid binding studies were conducted on an Arg2215Ala C2 domain
mutant due to its proximity to the hydrophobic region of platelet membranes. We were
able to express and purify all of the C2 domain mutants, and proper folding of these
mutants was verified using affinity pull-down assays. Phosphatidylserine membrane
binding ELISAs revealed that all the mutants studied were not able to bind to activated
platelet phosphatidylserine-containing membranes in activated platelets. Preliminary
intrinsic fluorescence analysis determined that Arg2320Ser was thermodynamically less
stable than wild type, but was still predominantly folded. Our data further supported our
activated platelet membrane binding mechanism that is centered on Arg2320, with two
hydrophobic spikes docked within the hydrophobic lipid bilayer of platelet membranes,
and nonspecific interactions between either the phosphate or carboxyl groups of
phospholipids and the underlying basic residues of C2 (Arg2209, Arg2215, Lys2183,
Arg2220, Arg2222, and Lys2249).
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Introduction

The encompassing processes of hemostasis are maintaining blood in the fluid state,
producing a blood clot confined to the area of vascular injury to prevent hemorrhage, and
inhibiting blood clot formation once a stable clot is formed. Our area of interest is blood
clot formation. Initially, the development of a hemostatic plug involves platelet adhesion
and aggregation to the damaged vessel wall, resulting in the production of a soft clot during
primary hemostasis. Immediately following the action of activated platelets, the
crosslinking of insoluble fibrin within the area of damage provides mechanical strength to
harden the clot during secondary hemostasis (Nemerson and Pitlick 1972). This study
explicitly focuses on the second hemostatic process, the formation of a fibrin clot, which
is dependent on protein blood coagulation factors (Davie and Ratnoff 1964). When the
activity of these coagulation factors is impaired, it causes blood disorders, generally
referred to as hemophilias. The disruption of hemostasis in patients with these disorders
can result in potentially life-threatening bleeding. Specifically, hemophilia A is caused by a
deficiency in coagulation factor VIII (fVIII). The activity of fVIII is dependent on its
ability to bind activated platelet surfaces (Gilbert and Arena 1996). Although previous
studies have shown that the second carboxy-terminal (C2) domain of fVIII is the primary
domain that interacts with activated platelet membranes (Arai et al. 1989), the molecular
basis of this interaction is poorly understood. We investigated this specific association
between the C2 domain and the components of platelet membranes to explain its role in
hemostasis and in causing hemophilia A.

Primary Hemostasis
Hemostasis describes the ability of an organism to prevent blood loss during injury. The
two distinct events during hemostasis are primary and secondary hemostasis (Palta et al.
2014). During primary hemostasis, a soft hemostatic platelet plug is formed, which
involves platelet adhesion and platelet aggregation (Nemerson and Pitlick 1972). This
platelet-rich soft plug can then provide a surface for the assembly of blood coagulation
factor proteins during secondary hemostasis, in which this soft clot is strengthened by a
hard fibrin clot (Davie and Ratnoff 1964).

Platelet Adhesion—The initial event during primary hemostasis in forming a soft hemostatic
plug is platelet adhesion onto damaged endothelial vessel walls (Nemerson and Pitlick
1972). Platelets are non-nucleated cells produced from megakaryocytes in bone marrow
that have a pivotal role in primary hemostasis. This adhesion process is mediated by the
large multimeric glycoprotein, von Willebrand factor (vWF), which contains three A
domains, three B domains, two C domains, and four D domains (Zhou 2012). vWF
provides the link between platelets and damaged vessels. Upon vascular damage, vWF is
immobilized to the damaged collagen-containing vessel walls by its A1 and A3 domains.
The A3 domain binds to fibrillary collagen type I and III (Huizinga et al. 1997), while the
A1 domain binds collagen type VI of the subendothelial connective tissue (Pareti et al.
1987). Platelets can then adhere to the injured vessels indirectly by binding to the
subendothelium-bound vWF. There are two receptors localized on platelet membranes
that recognize vWF: the glycoprotein Ib-IX-V (GPIb-IX-V) receptor complex and integrin
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αIIbβ3 (or also known as the glycoprotein IIb/IIIa complex) (Hantgan et al. 1990).
Glycoprotein GPIbα of the GPIb-IX-V complex binds to the vWF A1 domain, acting as
the initial tethering of platelets to the subendothelium surface (Emsley et al. 1998). Integrin
αIIbβ3 then recognizes an Arg-Gly-Asp sequence within the C1 domain of vWF (Beacham
et al. 1992). Under the localized high shear stress of blood flow around sites of vascular
damage, the globular conformation of vWF changes in a way that exposes available
receptor binding sites and thereby increases the interactions between vWF and platelets.

Platelet Aggregation—Once platelets adhere to the subendothelium by means of vWF, they
can then aggregate through platelet-platelet interactions to form a soft clot. The
mechanism in which platelets aggregate is dynamic and complex, but the fundamental
interaction is primarily mediated by integrin αIIbβ3, the transmembrane receptor that was
also involved in vWF-mediated platelet adhesion (Jackson 2007). These receptors located
on adjacent platelets can bind to fibrinogen, which allow the platelet-platelet interactions.
ADP binding causes fibrinogen deposition, further encouraging these platelet-platelet
interactions. During this process, platelets are also activated. The enzyme, scramblase, flips
phosphatidylserine lipids nonspecifically between the two lipid bilayers of platelet
membranes and this results in an increase in negatively charged phospholipids in the outer
leaflet of the platelet membranes following platelet activation (Bevers et al. 1983,
O’Donnell et al. 2014). These membranes can then provide a surface for secondary
hemostasis in which a fibrin clot can formed to stabilize and strengthen this initial clot.
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Secondary Hemostasis
Traditionally, the hemostatic process in forming a hard fibrin clot was explained by the
blood coagulation cascade model, which described a series of protein interactions
propagated by the proteolytic activation of clotting factors. These interactions distinctly
lead to the formation of a stable blood clot through the covalent crosslinking of insoluble
fibrin. This cascade model is composed of an extrinsic and intrinsic arm that converge at
a common pathway (Figure 1; Macfarlane 1964, Davie and Ratnoff 1964). The extrinsic
arm is stimulated by endothelial tissue damage, with the exposure of collagen to platelets,
while the intrinsic arm was stimulated by trauma within the vasculature. However, this
model was insufficient in explaining the entire blood clotting process, as each of these
pathways cannot function independently to promote a stable blood clot. Instead, a cellbased model is now used to explain the existing coagulation cascade, which describes
hemostasis in three distinct, but overlapping phases: initiation, amplification, and
propagation (Figures 2/3/4; Monroe and Hoffman 2006).
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Figure 1. Blood coagulation cascade. The traditional model of blood coagulation is termed the blood
coagulation cascade, composed of an intrinsic pathway and an extrinsic pathway that converge at the final
common pathway to generate fibrin that enables the formation of a stable blood clot. The intrinsic pathway
is stimulated by blood vessel damage, which activates fXII. Factor fXIIa then activates fXI, which activates
fXI to form the intrinsic tenase complex. The extrinsic pathway is stimulated by tissue damage, which
activates fVII. The tissue factor-fVIIa complex and the tenase complex both activate fX. In the final
common pathway, fXa forms the prothrombinase complex with fVa and activated platelets to generate
large burts of thrombin. Fibrinogen is then proteolytically converted to fibrin, which enable sthe formation
of a stable blood clot.
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Initiation—The first phase of hemostasis, initiation (or also traditionally known as the
extrinsic pathway of the blood coagulation cascade), provides low amounts of activated
coagulation factors and platelets (Figure 2). This phase is stimulated by tissue damage,
which results in the expression of tissue factor (TF) on the surface of endothelial cells.
Therefore, the initiation step is localized on TF-bearing cells, which are normally located
outside the vasculature (Monroe et al. 1996).

During tissue damage, coagulation factor VII is activated (fVIIa) by trace active proteases
circulating in the blood and TF is exposed to the bloodstream. Subsequently, fVIIa
associates with its transmembrane receptor, TF, for the activation of factor IX (fIX) and
factor X (fX) in small amounts (Lawson and Mann 1991; Monroe et al. 1996). Tissue
damage additionally causes platelet adhesion to collagen and other extracellular matrix
components of the damaged site, which promotes the secretion of partially activated factor
V (fVa). Factor V (fV) can also be activated by fXa or thrombin to enable the formation
of the prothrombinase complex, composed of fXa and fVa, on the surface of TF-bearing
cells (Monkovic and Tracy 1990; Monroe et al. 1996; Briede et al. 2001). This complex is
initially formed on TF-bearing cells to serve to convert sufficient amounts of prothrombin
into thrombin, which functions as an initiating signal for platelet activation. In contrast,
during the propagation phase, this complex is assembled on activated platelets to generate
a burst of thrombin (Rosing et al. 1985) for a variety of procoagulant functions leading to
the insoluble fibrin mesh.
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Figure 2. Phase 1 of hemostasis: initiation. The process of hemostasis has three distinct, but overlapping
phases: initiation, amplification, and propagation. The first phase, initiation is stimulated by tissue damage,
which activates fVII and platelets. Tissue factor exposed on the surface of cells binds to fVIIa, and activates
small amounts of fIX and fX. Activated platelets bind to collagen and activates fV. The prothrombina se
complex composed of fXa, fVa, and tissue factor, produces small amounts of thrombin on tissue factorbearing cells for the use of the second phase of hemostasis.
Amplification—The second phase of hemostasis is amplification, which results in the
increased level of activated coagulation factors (Figure 3). The small amounts of thrombin
produced during initiation is then able to activate factors V, VIII, and XI on platelet
surfaces during amplification (resulting in factors Va, VIIIa and XIa, respectively).
Thrombin also activates platelets during this phase, resulting in an increased level of
negatively charged phosphatidylserine headgroups exposed on the surface (or outer leaflet)
of platelet membranes (Bevers et al. 1983, O’Donnell et al. 2014). Mainly, amplification
sets the stage for large-scale thrombin production in the third phase, propagation.
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Figure 3. Phase 2 of hemostasis: amplification. The process of hemostasis has three distinct, but overlapping
phases: initiation, amplification, and propagation. The second phase, amplification, elevates the levels of
fVa, fXIa, fVIIIa, and activated platelets stimulated by sufficient amounts of thrombin generated during
initiation. These activated factors and platelets are then used in third phase, propagation, for large-scale
thrombin production.
Propagation—The third phase, propagation, takes place on the surface of these newly
activated platelets. It is traditionally known as the intrinsic pathway of the blood
coagulation cascade model. This phase contrasts with the initiation phase in that the
protein interactions are localized on activated platelet surfaces instead of on TF-bearing
cells (Rosing et al. 1985). At this stage, large bursts of thrombin are produced. Thrombin
then converts the soluble plasma protein, fibrinogen, into insoluble fibrin after a series of
protein interactions. The crosslinking of fibrin gathered at the site of injury entangles red
blood cells, leading to the formation of blood clots (Figure 4; Kanaide and Shainoff 1975).

The specific protein interactions of the propagation phase begin with the stimulation of
damaged blood vessels. The contact of factor XII to negatively charged surfaces
spontaneously causes fXII activation (to fXIIa) (Cochrane et al. 1973; Griffin 1978), which
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then activates factor XI. Factor XI can also be self-activated or activated by thrombin in
the presence of negatively charged surfaces (Naito and Fujikawa 1991). Following fXI
activation, fXIa converts fIX to fIXa (Fujikawa et al. 1974; Lindquist et al. 1978). The
thrombin-activated fVIIIa then acts as a cofactor to serine protease fIXa and binds to
phosphatidylserine exposed on the extracellular surface of activated platelets, forming an
important complex termed the intrinsic Xase (tenase) complex due to its role in the
activation of factor X (Bergsagsel and Hougie 1956; Dieijen et al. 1981). Subsequently, fXa
associates with fVa on activated platelet membranes to form the prothrombinase complex,
which causes large-scale thrombin production by activating prothombin (Rosing et al.
1985). Thrombin proteolytically converts the soluble precursor, fibrinogen, to insoluble
fibrin. This insoluble fibrin is then able to assemble into long fibrils that gather at the site
of injury, leading to the formation of a stable, hard blood clot (Kanaide and Shainoff 1975).
Due to the importance of the Xase complex (fVIIIa/fIXa/platelets) in promoting
hemostasis, the structural characterization of fVIIIa lipid binding is an important concern.
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Figure 4. Phase 3 of hemostasis: propagation. The process of hemostasis has three distinct, but overlapping
phases: initiation, amplification, and propagation. The third phase, propagation, is also traditionally
known as the intrinsic pathway of blood coagulation. Propagation is stimulated by vascular damage, which
activates fXII. Activated fXIIa then activates fXIa, which activates fIXa, allowing for the formation of
the intrinsic tenase complex composed of fVIIIa/fIXa/activated platelets. The tenase complex activates
fXa that is used for the formation of the prothrombinase complex on the surface of activated platelets. The
prothrombinase complex generates large-scale thrombin production, which then proteolytically converts
soluble fibrinogen to insoluble fibrin that assemble into long fibrils that gather at the site of injury to form
a stable, hard blood clot.
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Inhibition of the Blood Coagulation Process
Once a stable blood clot is formed, the blood coagulation process needs to be inhibited to
prevent thrombosis. Inhibition of the blood coagulation process is modulated by (1)
activated Protein C, (2) antithrombin III, and/or (3) tissue factor pathway inhibitor.

Activated Protein C—The Protein C anticoagulant pathway inactivates the glycoproteins (fVa
and fVIIIa) of the coagulation process and is mediated by thrombomodulin, a thrombinbinding protein present on cell surfaces (Esmon and Owen 1981). The thrombomodulinthrombin complex serves to activate Protein C, a serine protease that inactivates fVa and
fVIIIa upon binding phospholipid vesicles (Walker et al. 1979). Protein S acts a cofactor
to Protein C to enhance Protein C phospholipid binding, resulting in the increased rate of
glycoprotein inactivation (Walker 1981). Factor V can also serve to enhance inactivation
rates of fVIIIa in the presence of Protein S (Varadi et al. 1996). The inactivation of fVIIIa
can additionally be mediated by fXa, which can cleave at the same site as activated Protein
C (Eaton et al. 1986).

Antithrombin III—Another method of inhibition is through antithrombin III, a plasma
glycoprotein that serves as a cofactor to heparin to inhibit serine proteases such as
thrombin (Abildgaard 1968), fIXa, fXa (Kurachi et al. 1976), fXIa (Damus et al. 1973), and
fXIIa (Stead et al. 1976) by forming a covalent carboxylic ester bond with the active site
serine residue in the catalytic site of these proteases (Owen, 1975).
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Tissue Factor Pathway Inhibitor—A more recently discovered method of inhibition is through
the tissue factor pathway inhibitor (TFPI or also known as the extrinsic pathway inhibitor),
which inhibits the initiation of blood coagulation by preventing the TF-fVIIa complex
from activating factors fIX and fX (Sanders et al. 1985; Rao and Rapaport 1987; Broze et
al. 1988; Wun et al. 1988). This pathway starts with TFPI binding fXa (Sanders et al. 1985;
Rao and Rapaport 1987; Broze et al. 1988; Wun et al. 1988). This TFPI-fXa complex then
inhibits the TF-fVIIa complex by the formation of a larger TFPI-fXa-TF-fVIIa complex
(Broze et al. 1988).

The complete process of hemostasis is complex and involves several different
components. The focus of this study, however, is on the glycoprotein, blood coagulation
factor VIII. Its central role is involved in forming of the important intrinsic tenase complex
during propagation, which is essential in promoting the formation of a stable fibrin blood
clot during hemostasis.

Blood Coagulation Factor VIII
Factor VIII (fVIII) is a glycoprotein that is essential in promoting proper hemostasis. It is
primarily synthesized in liver sinusoidal cells (Webster 1971), but has been shown to be
synthesized in other tissues as well, such as in the spleen, lymph nodes, and kidney (Wion
1985). Mature fVIII is initially synthesized as a single polypeptide with the domain
structure A1-a1-A2-a2-B-a3-A3-C1-C2 and consists of 2332 residues (Figure 5; Vehar et

12

al. 1984; Toole et al. 1984). The A domains have short spacers (a1, a2, and a3) containing
acidic regions, harboring clusters of Asp and Glu residues.

Figure 5. A schematic view of the fVIII construct. First, fVIII is synthesized as a single 2332-residue
polypeptide chain with domains A1-a1-A2-a2-B-a3-A3-C1-C2. The lower-cased domains are acidic
linker regions. Cleavage at Arg1313 and Arg1648 result in fVIII processing, which is secreted from the
cell as an inactive heterodimer A1-a1-A2-a2-B/a3-A3-C1-C2. Factor VIII is then activated by
thrombin cleavage at Arg372, Arg740, and Arg1689, which results in fVIIIa. Sites for fVIIIa
inactivation are Arg336 and Arg562.
Upon secretion from the cell, fVIII is processed by cleavage occurring at the Arg1313 and
Arg1648 residues within the B domain of fVIII, resulting in a heterodimer consisting of a
heavy chain (A1-a1-A2-a2-B) and a light chain (a3-A3-C1-C2) that is held together by a
metal ion bridge (Figure 5; Vehar, et al, 1984; Kaufman et al. 1988). The light chain of
this inactive heterodimer is bound tightly in a noncovalent complex with the glycoprotein,
von Willebrand factor (vWF). The fVIII/vWF complex maintains fVIII stability in
13

circulation by preventing premature inactivation by activated Protein C and blocking
phospholipid interactions (Fay et al. 1991). During vascular injury, fVIII becomes
proteolytically activated into a heterotrimer (A1-a1/A2-a1/A3-C1-C2) either by thrombin
or fXa, which leads to the dissociation of fVIIIa from vWF upon removal of the acidic a3
region of fVIII (residues 1649-1689) (Eaton et al. 1986; Lollar et al. 1988). Thrombin
activates fVIII by cleaving at Arg372 and Arg740 in the heavy chain and Arg1689 in the
light chain (Eaton et al. 1986; Pittman and Kaufman 1988; Nogami et al. 2000). Factor Xa
can also activate fVIII by cleaving at the same sites as thrombin, but additionally, it can
cleave at Arg1721 (Eaton et al. 1986). However, the main activator of fVIII is thrombin
because vWF inhibits fXa proteolysis of fVIII, whereas vWF does not affect thrombin
cleavage of fVIII (Koedam et al. 1990).

An X-ray crystal structure of a B domain-deleted fVIII has been reported to a resolution
of 3.7 Å to demonstrate the unambiguous placement of the domains (Figure 6; Shen et
al. 2008). The function of fVIIIa is to act as a cofactor for serine protease fIXa on the
surface of activated platelets, which forms the intrinsic tenase complex during the
propagation phase of hemostasis to promote the formation of a stable blood clot (Dieijen
et al. 1981). Previous findings from various labs have shown that the C2 domain of fVIIIa
is the central domain involved in activated platelet membrane binding (Arai et al. 1989;
Foster et al. 1990).
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Figure 6. Factor VIII X-ray crystal structure. A 3.7 Å resolution X-ray crystal structure of a B domaindeleted fVIII heterodimer composed of a heavy chain (A1-A2) and a light chain (A3-C1-C2). The
structure showed unambiguous modeling of domains A1 (blue), A2 (green), A3 (blue), C1 (orange), and
C2 (pink) (PDB ID 2R7E; Shen et al. 2008).

C2 Domain of fVIII
Although fVIIIa contains five domains, the main domain of interest is the second carboxyterminal (C2) domain of fVIII. The C2 domain has been shown to have binding sites for
vWF (Saeneko et al. 1994), but the focus of this study will be on the structural basis for C2
domain binding to activated platelet membranes (Aria et al. 1989; Foster et al. 1990).
Currently, there is controversy in the phospholipid binding mechanism of fVIII C2
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domain. Previous studies have shown that residues 2303-2332 within the C2 domain are
important for phosphatidylserine (PS) lipid membrane binding due to the ability of the
2302-2332 peptide to inhibit fVIII PS membrane binding (Foster et al. 1990). In 1999, a
1.5 Å resolution X-ray crystal structure of human fVIII C2 domain revealed two
hydrophobic beta-hairpin loops that protrude from a ring of basic residues (Figure 7A/B;
Pratt et al. 1999). From this crystal structure, it was suggested that the C2 domainphospholipid binding interface was centered on Arg2220 (Figure 7C). This model had the
hydrophobic beta hairpin loops (Leu2251-Leu2252 and Met2199-Phe2200) and residue
Val2223 embedded within the lipid membrane. The model also included electrostatic
interactions between the underlying basic residues (Lys2227, Arg2220, Lys2249, and
Arg2215) and negatively charged phospholipid head groups of activated platelet
membranes (Figure 7C). In support of this binding mechanism, an electron
crystallographic structure of fVIII in its membrane-bound state was resolved to 1.5 nm
and revealed that a loop containing residues Trp2313-His2315 was involved in membrane
binding (Stoilova-McPhie et al. 2002). This binding mechanism, however, did not agree
with recent ELISA binding studies from our lab, which will be explained later in the
“Binding Analysis of Porcine C2 with 3E6 F AB and G99 F AB” section (Walter et al. 2013;
Brison et al. 2015). Due to the large number of basic residues underlying the hydrophobic
beta-hairpin loops, it is difficult to pinpoint the specific phospholipid binding site. Our
goal is to define this mechanism with less ambiguity. The relevance of focusing on this
mechanism is that when fVIIIa is unable to bind to activated platelet membranes, it causes
the blood disorder, hemophilia A.
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Figure 7. Factor VIII C2 domain X-ray crystal structure. A 1.5 Å resolution X-ray crystal
structure of human fVIII C2 domain (PDB ID 1D7P; Pratt et al. 1999). (A) A ribbon
diagram displaying the hydrophobic beta hairpin loops of hC2 include residues Met2199-Phe220
and Leu2251-Leu2252 (light gray). The ring of underlying basic residues consists of Arg2200,
Arg2215, Arg2320, and Lys2249 (blue). (B) Coulombic surface coloring (generated in Chimera)
shows the positively charged basic residues (blue) and the hydrophobic residues (light gray).
Negatively charged residues are red. (C) The previously proposed model of C2 domain lipid binding
centered on Arg2220. A loop containing residues Trp2313-His2315 (yellow) was hypothesized
to be involved in lipid binding (Stoilova-McPhie et al. 2002). The dotted line and gray tinted area
represents the phospholipid membrane of activated platelets.
Hemophilia A
Deficiency in fVIII clotting activity causes hemophilia A, an X-linked blood disorder that
prevents proper blood clot formation. It is estimated that 1 in 5,000 male births is affected
by hemophilia A worldwide (Soucie 1998). The other types of hemophilias are caused by
deficiencies in factor I (fibrinogen), factor II (prothrombin), factor V, factor VII
(proconvertin), factor X (Stuart-Prower factor), factor XI (which causes hemophilia C),
factor XII (Hageman factor), factor XIII (fibrin stabilizing factor), and factor IX (which
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causes hemophilia B) (Bolton-Maggs et al. 2004). Von Willebrand disease, caused by
deficiency in vWF, is another bleeding disorder that results in a similar phenotype as
hemophilias (Ginsburg et al. 1985). Hemophilia A, however, is the most common type of
hemophilia, representing 80% to 85% of the total hemophilia population (Srivastava et al.
2013). Individuals with this disorder are characterized as having severe, moderate, or mild
hemophilia, with fVIII activity levels of less than 1% of normal, 1% to 5% of normal, and
5% to less than 40% of normal, respectively. Phenotypes of patients with severe
hemophilia include two to three spontaneous bleeding incidents into joins or muscles each
month, while moderate and mild hemophilia only have seldom or none, respectively.
Abnormal and prolonged bleeding with trauma or surgery are overlapping characteristics
of all three types (Srivastava et al. 2013).

Hemophilia A is inherited in an X-linked recessive pattern, passed down by a pathogenic
variant of the fVIII gene (F8) located on the long arm of the X chromosome at position
28 (Xq28; Gitschier et al. 1984). There are many different possible mutations within the
fVIII gene that can affect protein clotting activity listed on the Factor VIII Gene Variant
Database provided by the European Association for Haemophilia and Allied Disorders
and the Structural Immunology Group from the University College London (Rallapalli et
al. 2014). The four types of DNA mutations that may occur are deletions, insertions
(including duplication), inversions, and substitutions (Tuddenham et al. 1994). These types
of mutations can either be caused by nonsense (a point mutation in which the codon is
changed to a stop codon), missense (a point mutation in which the amino acid is changed),
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splice site change, frameshift, large structural change (>50 bp), or small structural change
(<50 bp), mutations. Nonsense and missense mutations are point mutations that cause
substitution mutations, with missense mutations being the most common in hemophilia.
Splice site change mutations also primarily cause substitutions, but can additionally cause
deletion, duplication, and insertion. Frameshift, large structural change, and small
structural change mutations can cause deletion, duplication, or insertion. Large structural
changes can additionally cause inversion. Mild hemophilia A is predominantly caused by
substitution point mutations in the form of missense DNA mutations, while moderate
hemophilia A can be caused by a large mix of different mutation types. Severe hemophilia
A is primarily caused by debilitating substitution and deletion mutations in the form of
nonsense, missense, splice site change, frameshift, large and small structural change
mutations.

On rare occasions, hemophilia A can also be acquired through autoimmune processes in
which there is a spontaneous development of inhibitory antibodies against endogenous
fVIII (Lottenberg et al. 1987). Cases of acquired hemophilia A have occurred mostly in
postpartum women and in patients aged 62 years and beyond. These antibodies inhibit the
function of endogenous fVIII within the patient, causing the attenuation of hemostasis.
To mediate the effects of hemophilia A, replacement therapies have been developed.
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Hemophilia A Therapeutics
Therapeutics of hemophilia A include direct infusions of either plasma-derived or
recombinant human fVIII (hfVIII) concentrates for replacement therapy (Coppola et al.
2010). These can be either be used on-demand as episodic infusions, or be used to treat
severe hemophilia A prophylactically, i.e., receiving regular infusions of fVIII concentrates
for hemorrhage prevention. The advantage of prophylactic treatment over episodic
infusions is the reduction in the number of bleeding episodes, thereby improving patient
quality of life (Smith et al. 1996; Konkle et al. 2015). Plasma-derived human fVIII is
prepared by extracting and purifying the glycoprotein from cryoprecipitate prepared from
human plasma (Addiego et al. 1992). Complications associated with this are the
transmission of viral contaminations and diseases. Current technology has eradicated this
possibility by treating the plasma with viral inactivation methods and improved disease
detection (Centers for Disease Control 1988). Treatment with recombinant hfVIII for
replacement therapy is more common in the United States than the use of plasma-derived
hfVIII. These proteins are primarily produced by Chinese hamster ovary (CHO) or baby
hamster kidney (BHK) cells transfected with the human fVIII gene (Kaufman et al. 1988).
To ensure safety, the concentrated proteins are then subjected to viral inactivation
methods, even though they are considered free of viruses.

There are currently many recombinant fVIII products available. Common recombinant
fVIII therapeutic products include Advate (Baxter), Xyntha (Pfizer) and Kogenate FS
(Bayer Pharmaceuticals). Their doses are based on a person’s deficiency of fVIII activity,
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their weight, and the circumstance of bleeding. They are administered through intravenous
infusion via IV bolus as soon as the bleeding episode occurs to promote proper hemostasis
(McDaniel 2013). Recently in 2015, Adynovate (BAX 855), a PEGylated full-length
recombinant fVIII based on Advate, was approved for on-demand and prophylactic
treatment of hemophilia A (Konkle et al. 2015; Horling et al. 2016). Adynovate has an
extended half-life due to PEGylation of the recombinant fVIII and thus is an improvement
in hemophilia A therapeutics. In patients with mild or moderate hemophilia A,
prophylactic treatment may not be required. Treatment with desmopressin (or also known
as DDAVP), which increases the levels of fVIII in plasma by inducing secretion from
endothelial cells, instead of direct infusions of hfVIII is a viable alternative in this patient
population (Rose and Aledort 1991).

Inhibitory Antibody Development: Hemophilia A Treatment Complications
and Management of Inhibitor Development
Although these transfusions are highly effective, approximately 30% of the patients who
receive these direct infusions of human fVIII (hfVIII) eventually develop inhibitory
antibodies that attenuate or abolish the function of the newly infused hfVIII (Bray et al.
1994; Lusher et al. 2003). This complication leaves the individual with the inability to form
stable blood clots due to nonfunctional hfVIII being cleared from circulation. In these
cases, and in cases of acquired hemophilia A, several options for treatment are available.
Immune tolerance induction can be employed as an attempt to eradicate inhibitors and
normalize pharmacokinetic parameters by means of frequent
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administration of

concentrates long-term, with success rates between 60% and 80% (DiMichele and Kroner
2002). Often, immune tolerance induction is accommodated by immunosuppression of
either the T- or B-cell pathways to prevent the production of these inhibitory antibodies
by the use of immunosuppression agents such as corticosteroids (Miao 2010). Although
the mechanism of action is not well known, desmopressin (DDAVP) has been clinically
used as an immunosuppressant as well (Franchini and Lippi 2011). Bypassing agents, such
as activated prothrombin complex concentrates and recombinant fVIIa replacements, are
also commonly used as first-line therapies to treat patients with inhibitory anti-hfVIII
antibodies (Hoffman and Dargaud 2012). Adynovate (the PEGylated recombinant fVIII),
and rfVIIIFc (a fusion protein composed of a recombinant fVIII covalently attached to
the Fc domain of human IgG) may also be used in lieu of traditional recombinant fVIII
concentrates, as they have been shown to have an extended half-life in circulation (van der
Flier et al. 2015; Horling et al. 2016). Adynovate is also able to evade the immune response,
making it a better alternative for fVIII infusions (Horling et al. 2016). Porcine fVIII
(pfVIII) as a second-line therapeutic is another option due its low cross-reactivity to antihfVIII antibodies, especially inhibitory antibodies that prevent proteolytic activation of
fVIII, relative to hfVIII (Hay et al. 1996; Barrow and Lollar 2006; Brison et al. 2015). Other
reasons pfVIII is an appropriate fVIII replacement is that pfVIII is more stable and more
active due to the A2 domain being in a tighter complex within the active form of pfVIII
(Lollar et al. 1992).
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The antibodies developed against fVIII can either be completely or incompletely
inhibitory, which corresponds to either type I or type II inhibition behavior, respectively
(Gawryl and Hoyer 1982). The epitopes of inhibitory antibodies are primarily located in
the A2, A3, and C2 domains of fVIII (Fulcher et al. 1985; Scandella et al. 1989). Within
the C2 domain, there are 5 different structural epitopes to which these inhibitory antibodies
can bind, and display two main mechanisms of inhibition (Meeks et al. 2007). Classical (e.g.
3E6 and BO2C11) antibodies bind at either group A, AB, or B epitopes and inhibit the
function of fVIIIa by blocking phospholipid and/or vWF binding (Figure 8; Arai et al.
1989; Barrow et al. 2001). The other, “nonclassical”, mechanism of inhibition prevents
thrombin or fXa activation of fVIII, by antibodies (e.g. G99) that bind at either group BC
or C epitopes of C2 (Meeks et al. 2008).

23

Figure 8. Examples of the inhibitory binding epitopes of the C2 domain. A 2.47 Å resolution X-ray
Crystal ternary structure of hC2 (pink)/G99 F AB (yellow)/3E6 F AB (dark green) (pdb ID 4KI5;
Walter et al. 2013) superimposed with a 2.0 Å crystal structure of hC2/BO2C11 F AB (blue) (pdb ID
1IQD; Spiegel et al. 2001). 3E6 and BO2C11 are both classical antibodies that bind at either the A
or AB epitope of C2, while the nonclassical antibody, G99, binds to the BC epitope of C2.

Structural Characterization of Human fVIII C2 Domain Interactions with
Antibodies 3E6 FAB and G99 FAB
Specific residue interactions between the two classes of anti-C2 inhibitory antibodies and
human fVIII C2 domain were elucidated in a 2.47 Å resolution crystal structure of a ternary
complex (C2 domain/3E6 F AB/G99 F AB), which was solved in our lab (Figure 9, Walter
et al. 2013).
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Figure 9. An X-ray Crystal structure of a ternary complex (hC2 domain (pink)/3E6 FAB (yellow)/G99
FAB (dark green)) determined to 2.47 Å resolution (pdb ID 4KI5; Walter et al. 2013).
This revealed that the classical epitope face of C2, where 3E6 binds, has a positively
charged surface potential (Figure 10A) that interacts electrostatically with the oppositely
charged surface of the 3E6 variable region (Figure 10B; Walter et al. 20013). Residues
Lys2183 and Gln2213 in C2 are 80% buried upon binding 3E6 F AB, based on analysis using
NACCESS (S. Hubbard and J. Thornton 1992-6), which divides the measured buried
surface area by the free accessible surface area (Walter et al. 2013). Lys2183 has a possible
cation- interaction with Trp90 of 3E6 F AB (Figure 10C).
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Figure 10. A coulombic surface coloring (generated in Chimera) of a 2.47 Å resolution X-ray crystal
structure of the 3 E6 FAB epitope in human C2 domain and of the 3E6 FAB surface where human C2
binds. (A) The classical epitope face of hC2 where 3E6 FAB binds is predominantly negatively charged
(blue) and (B) the variable region of 3E6 F AB has a positively charged surface (red) that interacts with
hC2. White colors represent hydrophobic residues. (C) Specific residue interactions of 3E6 F AB (yellow)
and hC2 (pink) involve Asp2187 and Lys2183 of hC2 and Ser30, Ser91, and Trp90 of 3E6 F AB
(PDB ID 4KI5; Walter et al. 2013).
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Similarly, the nonclassical epitope face where G99 FAB binds showed an electrostatic
interaction where the nonclassical G99 F AB has a negatively charged anionic pocket
(Figure 11A) that allowed for the basic Lys2227 residue within the nonclassical epitope
face of C2 to bind (Figure 11B).

Figure 11. A coulombic surface coloring (generated in Chimera) of a 2.47 Å resolution X-ray Crystal
structure of the G99 FAB epitope in human C2 domain and of the G99 FAB surface where human C2
binds. (A) The nonclassical epitope face of hC2 is predominantly positively charged (blue), (B) while the
surface potential for the G99 pocket where hC2 binds is negatively charged (PDB ID 4KI5; Walter et al.
2013).
To understand the lowered cross-reactivity of pfVIII, a crystal structure of pfVIII C2
domain was determined to a resolution of 1.7 Å by a former member of our lab (Brison et
al. 2015). This structure was superimposed with the ternary hC2/3E6 FAB/G99 F AB
complex, revealing the specific differences between hC2 and pC2 in terms of the classical
and nonclassical epitope faces. Overall, the tertiary structures are similar with a root-meansquare deviation (RMSD) value of 0.282 Å (Figure 12) and have a sequence identity of
80%.
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Figure 12. The crystal structures of human C2 (pink, PDB ID 4KI5) and porcine C2 (yellow, PDB ID
4MO3) superimposed with an RMSD of 0.842 Å (Walter et al. 2013; Brison et al. 2015).
The electrostatic surface potentials of hC2 and pC2 reveal that the differences between the
3E6 classical epitope faces are not as striking as the differences between hC2 and pC2 G99
nonclassical epitope faces. Sequence alignment shows that the differences between the
human and porcine classical epitope faces are functionally minimal, with the most drastic
change being the basic Lys2207 residue to a polar, uncharged Gln2207.

This is further

supported by observing that the electrostatic surface potentials of the classical epitope
faces in the human and porcine structures are both primarily positive (Figure 13A/B).
However, the surface potential of the nonclassical epitope face is primarily negatively
charged in pC2 due to the acidic Glu2227 residue, whereas in hC2, the same residue is a
basic Lys2227 (Figure 13C/D). Functional studies agreed with the observed differences
between the two epitope faces between human and porcine C2 domains, providing a
structural rationale for the observation that porcine fVIII is an effective alternative to
human fVIII for replacement therapy in patients with nonclassical anti-human fVIII C2
inhibitory antibodies.
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Figure 13. A coulombic surface coloring (generated in Chimera) of a 2.47 Å resolution X-ray Crystal
structure of fVIII human C2 domain (PDB ID 4KI5, Walter et al. 2013) and a 1.4 Å resolution Xray Crystal structure of fVIII porcine C2 domain (PDB ID 4MO3, Brison et al. 2015) visualized in
Chimera. The differences between the 3E6 F AB epitope faces of hC2 (A) and pC2 (B) are electrostatically
similar. In contrast, the G99 F AB epitope faces of hC2 (C) and pC2 (D) are oppositely charged, which
demonstrates the structural reasoning as to why the human C2 antibody, G99 F AB, has a high affinity for
hC2, but does not bind pC2.
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Binding Analysis of Porcine C2 with 3E6 F AB and G99 FAB
Inhibitory antibody binding analyses employing enzyme-linked immunosorbent assays
(ELISA) showed that the binding affinities between human and porcine C2 with 3E6 mAb
are more similar than with G99 mAb (Brison et al. 2015). Human and porcine C2 3E6
mAb binding had approximate K D values of 2.2 and 4.3 nM, respectively (Figure 14A). In
contrast, hC2 bound G99 mAb with high affinity, while porcine C2 was unable to bind
G99 mAb (Figure 14B). Although 3E6 mAb binding was similar in both human and
porcine C2, 3E6 mAb inhibits human fVIII activity significantly more than that of porcine
fVIII, revealed in a Bethesda assay, with inhibitory titers of 0.8 BU/mg IgG and 41 BU/mg
IgG, respectively (Figure 14C; Brison et al. 2015). Porcine fVIII activity was not affected
by G99 mAb, which is consistent with its inability to bind G99 FAB (Brison et al. 2015).
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Figure 14. Inhibitory antibody binding analyses using ELISAs showed (A) 3E6 mAb binding was not
significantly different between porcine (closed squares) and human (open circles) C2, (B) while G99 mAb
was only able to bind human C2 (open circles). (C) Factor VIII inhibition studies through a Bethesda
assay showed G99 mAb did not decrease porcine fVIII activity (open triangles), but it did significantly
inhibit human fVIII activity (open circles). 3E6 mAb inhibited human fVIII activity (closed circles)
significantly more than porcine fVIII activity (closed triangles) (Brison et al. 2015).
To examine which epitope of C2 binds PS-containing membranes, an ELISA detecting
antibody binding of phosphatidylserine-bound fVIII C2 was employed by Brison et al. in
2015. This assay revealed which epitope was more solvent accessible when C2 is
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immobilized on a membrane. Membrane-bound C2 was able to bind G99 mAb (with an
affinity of 15.5 mM), but not 3E6 F AB (Figure 15). This led to the conclusion that C2 binds
membranes at the classical epitope face, where 3E6 binds, and not the nonclassical epitope
face, where G99 binds. Because the C2 classical epitope face is centered on Arg2320,
further studies were focused on this residue in C2.

Figure 15. ELISA studies for phosphatidylserine (PS)-bound C2 and the two antibodies showed that the
G99 epitope face was more solvent accessible than the 3E6 epitope face of C2. PS -bound C2 was able to
bind G99 mAb, but not 3E6 mAb indicating that the PS binding occurs at the 3E6 epitope face (Brison
et al. 2015).

Goals of this Study
Currently, the fVIII C2 domain binding mechanism of phosphatidylserine-containi ng
activated platelet membranes remains controversial. The docking of the hydrophobic beta
hairpin loops in C2 to platelet membranes is universally accepted, however the controversy
lies within which epitope face docking occurs and with that, which underlying basic
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residues interact with the negatively charged phospholipids of the activated platelet
membranes (Figure 7A/B). Our previous research supports a new binding model that is
centered on Arg2320 within the classical epitope face. Therefore, we studied the two
naturally occurring hC2 mutants Arg2320Ser and Arg2320Thr that cause mild and
moderate hemophilia A, respectively (Rallapalli et al. 2014). It is plausible that these
mutations yield non-functional fVIII due to the inability of these mutants to bind
membranes based on the concept that Arg2320 is one of the underlying basic residues that
stabilize the membrane-C2 interaction. There are two other mutations, Arg2320Trp and
Arg2320Met that occur naturally at this residue, but they were not examined. Arg2320Trp
causes severe hemophilia A and likely does not fold correctly. Expression of the
methionine mutation was attempted; however, the protein was unstable and could not be
isolated in pure form. We also studied was an unnatural mutation, Arg2215Ala, because
Arg2215 appears to be a positively charged residue that is positioned within the
hydrophobic lipid bilayer during lipid binding and likely causes an unfavorable interaction.
This observation led us to hypothesize that this C2 mutant would have a greater binding
affinity to phospholipid membranes due to the removal of the positive charge. Because the
fVIII C1 domain has also been shown to aid in the binding of factor VIII to phospholipid
membranes (Meems et al. 2009; Lu et al. 2011), we extended two naturally occurring Arg
mutations (Arg2159H and Arg2163H) to the isolated C2 domain of human fVIII. The C1
and C2 domains have a 40% sequence identity and a high structural homology, with an
RMSD value of 3.08 Å (Figure 16). Studies with the Arg2163H mutant would be
complementary to our hC2 mutant studies due to this mutation being at the same structural
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location as the Arg2320 residue within the C2 domain (Figure 16). However, these hC1
mutants were difficult to purify and no further studies could be carried out. With these
hC2 domain mutants, we analyzed (1) hC2 protein stability of Arg2320Ser and
Arg2320Thr, and (2) hC2 membrane binding of Arg2320S, Arg2320Thr, and Arg2215Ala.
In addition to studying these mutants, we also determined the X-ray crystal structure of
wild type pC2 in complex with the soluble headgroup of phosphatidylserine, O-phosphoL-serine (OPLS).

Figure 16. Structural alignment of the C1 (green) and C2 (pink) domains of human fVIII, with an
RMSD value of 3.08 Å. Arg2320 within the C2 domain is in the same residue location as Arg2163
in the C1 domain. Arg2215 in the C2 domain and Arg2159 in the C1 domain were also of interest.
These arginines were mutated to Arg2320Ser, Arg2320Thr, Arg2215Ala, Arg2163His, and
Arg2159His for further analysis of C2 phospholipid membrane binding. (PDB ID 2R7E; Shen et al.
2008)
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(1) Evaluation of Mutant Protein Stability—Functional studies of C2 Arg2320Ser and
Arg2320Thr mutants were investigated to ensure proper folding and to analyze protein
stability compared to wild type. These studies included (1) affinity pull-down assays and
(2) intrinsic fluorescence. Pull-down assays showed whether mutants bound to anti-C2
antibodies. The nonclassical G99 antibody was used to assess proper protein folding, while
the classical 3E6 antibodies determined whether the mutation in the classical epitope
affected antibody binding. Intrinsic fluorescence evaluated tertiary structure stability, by
measuring protein unfolding upon chemical denaturation.

(2) Membrane Binding Analysis—Analysis of platelet membrane binding employed (1) X-ray
crystallography and (2) ELISAs. X-ray crystallographic analysis of the structure of wild
type porcine C2 bound to the headgroup of phosphatidylserine, OPLS, allowed for
elucidation of the structural interactions between fVIII pC2 and phosphatidylserine. This
method first required the production of a high-quality protein crystal. Soaking the crystal
in a solution of a small molecule allows for the molecule to diffuse into the crystal lattices
if the interactions are favorable. The crystal is then exposed to X-rays, resulting in
diffraction patterns based on the placements of atoms within the protein crystal. These
diffraction patterns are then integrated and transformed using XYZ software to produce
an electron density map. The locations of each atom within a protein can then be modeled
into the electron density. As a result, an atomic resolution structural model of a protein is
constructed. The main descriptors for evaluating the agreement between the protein model
and the X-ray diffraction data are the R values. These R values measure how well the
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crystallographic model predicts the experimental electron density map. The lower the R
values, the better the fit between the model and the density map. R free specifically describes
the fit following removal of 10% of the reflections data to verify unbiased fitting (Brunger
1992). Therefore, R free should always be larger in value than R work. In cases when R free is
lower than Rwork, the model had been biasedly over-fitted into the density map. An R value
of approximately 0.6 or higher indicates random fitting of a model, while R values below
0.2 infer high quality fitting (Brunger 1992). Next, the analysis of membrane binding in
the Arg2320Ser, Arg2320Thr, and Arg2215Ala hC2 mutants were determined using
ELISAs. This is a colorimetric method that detects the amount of proteins bound to lipidcoated plates as a function of increasing protein concentration.

The main goal of this study was to elucidate the binding mechanism of fVIII to the
phosphatidylserine-containing activated platelet membranes. Comprehension of the
binding mechanism of fVIII allows for us to contribute to the advancement of hemophilia
A therapeutics. With this information, we can help to improve recombinant fVIII
replacement therapies by identifying potentially beneficial mutations that will cause an
increase in coagulant activity.
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Materials and Methods

Human C2 Cloning and Expression
The gene for wild type human fVIII C2 domain (residues 2171-2332) in a pET15b plasmid
was prepared previously (Spiegel et al. 2004). Subsequently, former group members cloned
this gene into a pSV plasmid. The human C2 (hC2) gene was excised from plasmid pSV in
a 30 l double digestion reaction containing 1 g of hC2 pSV, 1x Cutsmart Buffer, 10 U
BamHI, and 10 U XhoI. The restriction enzymes were purchased from New England
Biolabs Inc. Vector pET32a(+) purchased from GenScript was also double digested using
the same protocol. These reactions were incubated for four hours at 37C. A 2% (w/v)
agarose gel was used to verify cleavage. The cleaved pET32a (+) plasmid and hC2 gene
were extracted from the gel using the Qiagen QIAquick Gel Extraction Kit. Cleaved hC2
and pET32a(+) was ligated with a 3:1 ratio of insert to vector using T4 DNA ligase and
1x T4 DNA ligase buffer. This reaction was incubated at 24C for 10 minutes and ligase
was heat-inactivated at 65C for 10 minutes. The pET32a(+) vector allows for the
expression with an N-terminal thioredoxin/(His)6/S tag, and an enterokinase cleavage site
(Figure 17). The sequence of the ligated vector was then verified by the Nevada Genomics
Lab and transformed into New England Biolabs SHuffle B-line cells. Colonies were
selected from Luria Bertani (LB) broth, ampicillin 50 g/ml (amp 50) selection plates. One
single colony was chosen and grown in 10 mL of LB amp 50 media for 16 hours at 30C to
produce a seed stock for large-scale protein expression.
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Figure 17. pET32a (+) vector construct (LaVallie et al. 1993; Novagen). The human fVIII C2
domain gene was inserted between XhoI and BamHI. Expression of C2 included thioredoxin/6 His/S
tags. Enterokinase cleavage separates the thioredoxin/6 His/S tags from C2.
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Site Directed Mutagenesis of Human C2 and C1 Domain Genes
Human C2 (R2320S, R2320T, and R2215A) and C1 (R2159H and R2163H) domains were
constructed using the Agilent Technologies QuikChange Lightning Site-Directed
Mutagenesis Kit with pET32a(+)/6His-thioredoxin-S-fVIII C2 and C1 plasmid templates,
respectively. Primers for the mutations were designed based on recommendations from
the Agilent Technologies

website and were purchased from Integrated DNA

Technologies.

Mutagenesis of wild type genes of human C2 and C1 isolated domains was performed
using a QuikChange Lightning Site-Directed Mutagenesis Kit from Agilent Technologies.
The temperatures for denaturation, annealing, and extension were 95C, 60C, and 68C,
respectively, with 18 total cycles.

DNA Extraction
To extract the plasmids containing the hC2 mutants from the XL10-Ultracompetent cells,
the QIAquick PCR purification kit purchased from Qiagen was used. The overnight cells
suspended in 950 l of LB-Amp50 were pelleted at 4969 x g and resuspended in 500 l of
P1 buffer. P2 and N3 buffers were added at 500 l and 700 l, respectively, and mixed by
inversion. The solutions were centrifuged for 10 minutes at 17,000 x g and the supernatant
was transferred to a spin column that contained resin that bound DNA. The column was
washed with 500 l of PB and 750 l of PE buffer. The plasmids were eluted with 50 l
of nanopure water.
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DNA Sequencing
Sequencing at Nevada Genomics allowed for verification of the DNA mutations. Each
DNA mutation had two samples prepared with either T7 promoters or T7 terminators due
to the average reliable sequencing results extending to approximately 500 to 600 base pairs.
From the T7 promoter, the thioredoxin/His/S tags alone contained 560 base pairs prior
to our gene inserts. T7 terminators were closer to our insert and used to verify our
mutations more reliably. Samples were prepared with 880 to 3500 ng of DNA and 10
picomoles of primer.

Transformation of Competent SHuffle ® T7 B Cells with Mutated Plasmids
Subsequently, chemically competent SHuffle® T7 B E. coli cells purchased from New
England Biolabs Inc. were transformed with pET32a(+) plasmids encoding each hC2 and
hC1 mutant. Approximately 100 ng of DNA were incubated with the competent cells for
30 minutes on ice. They were then heat shocked at 42C for 30 seconds, with a 5-minute
recovery time on ice. Room temp LB medium was added up to 1 mL in the mixture and
shaken at 200 rpm at 30C for 60 minutes. The cells were spread onto LB/ampicillin50
plates. A single colony was chosen to prepare a seed stock for subsequent overexpression
of the mutant proteins.

Overexpression and Purification of hC2 and hC1 Mutants
Overexpression of each hC2 and hC1 mutant was carried out in 1 L of LB-amp50 broth
with 10 g dextrose incubated at 30C. Cells were inoculated with saturated 10 mL
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overnights and induced with 0.4 M isopropyl-β-D-thiogalactopyranoside (IPTG) when
OD600 readings reached 0.5-0.6 AU. The temperature was adjusted to 16C following
induction. After approximately 20 hours of expression at 16C, the cells were harvested at
6000 rpm in an F12-6x500 LEX rotor from Thermo Scientific for 10 minutes. The cells
were resuspended in lysis buffer (300 mM NaCl, 20 mM Tris-HCl pH 7.5, 10 mM
imidazole pH 8.0, 10.0% (v/v) glycerol, and 0.5% (v/v) Triton X-100) and lysed by
sonication using a Branson Sonifier 450 probe at power output five and duty cycle 50%
for 90s. To remove cell debris, the lysed cells were centrifuged at 17,500 rpm in an F2012x50 LEX Thermo Scientific rotor for 35 minutes at 4°C. The high-speed supernatant
was filtered through a 5 m, then a 0.45 m filter before purifying with 1 mL of settled
TALON® cobalt immobilized metal affinity chromatography resin per 2 L of E. coli cell
growth. Wash steps included 30 column volumes (CV) of lysis buffer and 30 CV of wash
II buffer (150 mM NaCl, 20 mM Tris-HCl pH 7.5, 10 mM imididazole pH 8.0, and 10%
(v/v) glycerol). The protein was eluted with elution buffer (150 mM NaCl, 20 mM TrisHCl pH 8.0, 150 mM imidazole pH 8.0, and 10% (v/v) glycerol) following a 10-minute
incubation time and dialyzed with 500 mL of storage buffer (150 mM NaCl, 25 mM TrisHCl pH 8.0, and 10% (v/v) glycerol) for every 15-20 mL of eluted protein sample. The
resin was cleaned with recharge buffer (3 mM NaCl and 20 mM MES pH 5.0) and stored
in 20% (v/v) ethanol.
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Recombinant Enterokinase Cleavage
The hC2 mutants were cleaved with recombinant enterokinase to remove the
thioredoxin/His6/S tag. Four units of enterokinase were used to cleave every 1 mg of hC2
protein. For every 1 unit of enterokinase, 25 l of rEKapture agarose resin were used to
remove the enzyme. Removing the tags from the cleaved protein required 500 l of
TALON resin. Both resins allowed for hC2 to be collected in the initial flow through due
to its inability to bind either resin.

HiTrap Capto S Column Purification
When necessary, impure protein samples were purified on a 5 mL HiTrap Capto S strong
cation exchanger column (GE Healthcare Life Sciences) connected to a fast protein liquid
chromatography (FPLC) device, AKTAprime Plus manufactured by GE Healthcare Life
Sciences. The column was equilibrated in buffer A (50 mM MES pH 6.5). Protein samples
were diluted 1:10 into buffer A to prevent premature elution and precipitation. The diluted
samples were loaded onto the column with a 10 mL Superloop. Buffer B (50 mM MES
pH 6.5 with 1 M NaCl) was used to elute the protein with a gradient setting of 50% Buffer
B in 20 CV. Elution of the proteins typically occurred at approximately 18% (180 mM
NaCl) buffer B. The column was cleaned with 5 CV 1 M NaCl and 5 CV of 1 M NaOH
after each injection and stored in 200 mM sodium acetate in 20% (v/v) ethanol.
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Mass Spectrometry
Protein samples were prepared by diluting the proteins to 10 M with nanopure water.
Either 1 or 3 l of sample was injected into the Thermoscientific Ultimate 3000 UHPLC
connected to a C18 column (Kinetex 2.6 m 100 Å) in-line with an Expression LCMS
mass spectrometer (Advion).

Affinity Pull-Down Assays
Thioredoxin fusion hC2 mutants were incubated in 50 l of TALON resin for 15 minutes
and washed four times with five CV of storage buffer (150 mM NaCl, 25 mM Tris-HCl
pH 8.0, and 10% (v/v) glycerol). Antibodies were similarly incubated for 15 minutes and
washed five times with five CV of storage buffer. The mass ratio of hC2 to antibody was
2:3 (50 g of hC2 and 75 g of antibody). The complex was eluted from the resin after a
5-minute incubation time with 2 CV of elution buffer (150 mM NaCl, 20 mM Tris-HCl
pH 8.0, 150 mM imidazole pH 8.0, and 10% (v/v) glycerol). The elution step was repeated
to ensure complete elution of the protein. Each elution fraction was analyzed with SDSPAGE.

Enzyme-Linked Immunosorbent Assays (ELISAs)
Nunc-Immuno MicroWell PolySorp 96 well solid plates were coated with 80% 1,2dioleoyl-sn-glycero-3-phosphocholine

(DOPC),

5%

1,2-dioleoyl-sn-glycero-3-

phosphoethanolamine (DOPE), and 15% 1,2-dioleoyl-sn-glycero-3-phospho-L-seri ne
sodium salt (DOPS) at 10 g/ml. These lipids were purchased from Avanti Polar Lipids
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Inc. (Alabaster, AL) as a 10 mg/ml stock dissolved in chloroform and were diluted to 10
g/ml with methanol before plate coating. Negative control wells were coated with 100%
DOPC at 10 g/ml. The wells were then blocked with a 1% (w/v) bovine serum albumin
(BSA)/50 mM Tris-HCl pH 7.5/0 mM, 20 mM, 85 mM, or 150 mM NaCl solution with a
45 minute incubation time at 37C and shaking at 75 rpm. Protein samples were prepared
with serial dilutions of 1:2 in 1% (w/v) BSA/50 mM Tris-HCl pH 7.5/0 mM, 20 mM, 85
mM, or 150 mM NaCl solution with initial protein concentrations of either 2000 nM, or
4000 nM for 12 samples total. These samples were incubated for 90 minutes. Subsequently,
Ni-NTA•HRP diluted to 1:1500 (in 1% (w/v) BSA/50 mM Tris-HCl pH 7.5/0 mM, 20
mM, 85 mM, or 150 mM NaCl solution) was incubated for 30 minutes. Lastly, 2,2′-Azinobis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) was the colorimetric reagent was used
to detect binding at 405 nm after incubation times of 30 minutes, 45 minutes, 1 hour, 1.5
hours, and 2 hours. All incubation steps were at 37C and shaken at 75 rpm. Between each
incubation, the wells were washed with a 1% (w/v) BSA/ 50 mM Tris-HCl pH 7.5
solution.

Intrinsic Fluorescence
Chemical denaturation of mutants using a gradient of guanidine-HCl was monitored by
intrinsic fluorescence. A 2 mL native sample was prepared with a protein concentration of
0.1 mg/ml and diluted with a buffer composed of 150 mM NaCl, 25 mM Tris-HCl pH
8.0, and 5% (v/v) glycerol. Additionally, a denatured sample was prepared with the same
protein concentration and with the same buffer conditions, but with 6 M guanidine-HCl.
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The native protein sample was titrated with the denatured sample by removing either 100
or 125 l from the native sample and adding back the same amount removed with the
prepared denatured sample for a total of either 23 (for 100 l titrations) or 19 (for 125 l
titrations) samples. Each sample was excited at 280 nm and emission spectra were collected
between 300-400 nm with a 1 nm step size and an integration time of 1 second. The slit
widths for both excitation and emission were 0.69 mm in a Photon Technology
International Fluorometer (Horiba Scientific).

X-Ray Crystallography
A porcine fVIII C2 domain crystal was prepared by a former group member, Caileen
Brison, using the hanging drop vapor diffusion method with a 2:1 ratio of crystallization
buffer (0.1 M CHES (pH 10.4), 0.1 M magnesium acetate, and 10% (v/v) ethanol) and 2
mg/mL porcine C2 domain. This porcine C2 domain crystal was soaked with a 5 mM
solution of the headgroup of phosphatidylserine, OPLS. Diffraction data were collected at
beamline 5.0.1 at the Advanced Light Source (Lawrence Berkeley National Labs, Berkeley,
CA). These diffraction data were indexed, merged and scaled with HKL2000 (Otwinowski
and Minor; HLK Research, Inc. Charlottesville, VA), and the phases were determined by
molecular replacement using Phaser within the Phenix software package. The previously
published structure of porcine C2 (PDB ID 4MO3; Brison et al. 2015) was used for Phaser
molecular replacement. Initial refinement with Phenix.refine included settings: 3 cycles,
rigid body, occupancies, and individual B-factors. The program, Coot (Crystallographic
Object-Oriented Toolkit), provided a means to manually change the locations of the atoms

45

to fit the electron density map. After each set of manual refinements within Coot, an
automatic refinement of the model was performed using Phenix.refine (Afonine et al.
2012) with the refinement parameter settings: 10 to 30 cycles, XYZ coordinates, real-space,
TLS parameters, simulated annealing (torsion angles), occupancies, and individual Bfactors. These settings were chosen based on several 3-cycle refinements with various
combinations of settings. The TLS parameters setting is especially important in that it is a
relatively new parameter that improves refinement (Zucker et al. 2010). For this structure,
this parameter reduced Rwork by 7.6%. The combination of parameter settings that
provided the lowest R free and Rwork numbers were the parameters used for further
refinements. Individual water molecules were added with the Phenix.refine program during
the last few sets of refinements by including the ‘update waters’ setting. These waters were
manually modeled in Coot and again, automatically refined in Phenix.refine. OPLS was
manually added in Coot where there was positive density that was unaccounted for, then
automatically refined in Phenix.refine. Secondary structure was predicted using the
secondary structure assessment program STRIDE (Frishman and Argos 1995) and
assigned manually in PyMol.
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Results

Mutant hC2 Expression and Purification
Production and isolation of hC2 mutants with immobilized metal affinity chromatography
(IMAC) TALON® cobalt resin were successful, albeit in low yields with low purity (Table
1, Figure 18A). Additional purification steps employing HiTrap Capto S cation strong
exchanger columns improved the purity of the thioredoxin fusion and the enterokinasecleaved proteins (Figures 18B/C/D/E).
Table 1. Approximate average protein yields per 6 L E. coli growths and percent recovery yields following
recombinant enterokinase cleavages.
Protein

Average Yields for 6 L of

% Recovery of Protein Following

Overexpression (Post IMAC)

Enterokinase Cleavage

Wild Type hC2

~30 mg, ~90% pure

~13%

hC2 R2320S

~5 mg, ~60% pure

~20%

hC2 R2320T

~ 5 mg, ~50% pure

~20%
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E

Figure 18. Purification and Analysis. SDS-PAGE results for hC2 Arg2320Ser following purification
and cleavage with recombinant enterokinase. (A) Arg2320Ser hC2 thioredoxin fusion samples with a
molecular weight of 35.8 kDa following immobilized metal affinity chromatography with TALON resin
IMAC were visualized on SDS-PAGE. All lanes are of the post IMAC samples, but lane 1 was
purified protein expressed with an addition of 10 g of dextrose. (B) Samples combined from lanes 3 and 4
of gel A were purified with a HiTrap Capto S column. Lane 2 shows the eluted peak number 3 that
contained the purified Arg2320Ser hC2 thioredoxin fusion protein. Lanes 3 and 4 shows eluted peak 2
and the flow through, respectively, contained the contaminants in the post IMAC sample. (C) The
hC2Arg2320Ser thioredoxin fusion protein was cleaved with recombinant enterokinase and had a
molecular weight of 18.7 kDa following cleavage (lanes 2 and 3). (D) The two cleaved samples from gel
C were combined and further purified using a HiTrap Capto S column. (E) The UV chromatogram
(blue) profile of the Capto S column purification of recombinant enterokinase cleaved Arg2320Ser mutant
shows the flow through peak (peak 1), removing unwanted contaminants and the elution peak (peak 2)
containing the cleaved Arg2320Ser mutant. The elution gradient is indicated by the green graph. Peak 2
corresponds to lane 1 in D.
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Mass Spectrometry
Mass spectrometry results indicated correct protein expression and cleavage at the correct
site. DNA sequencing results also verified correct hC2 mutant sequences (Appendix
Figure 1). The mass of cleaved wild type hC2 was 18.796 kDa. Masses of mutants hC2
Arg2320Ser and Arg2320Thr cleaved were 67 Da and 57 Da and below that of wild type,
respectively (Table 2). This was expected since serine and threonine are 69 Da and 55 Da
lower in mass, respectively, than arginine. Similarly, wild type thioredoxin (trx) fusion hC2
protein had a mass determined to 35.724 kDa, while hC2 Arg2320Thr-trx fusion had mass
that was 56 Da lower. The purity of the hC2 Arg2320Ser-trx fusion sample for mass
spectrometry was low compared to that of WT and Arg2320Thr, likely contributing to the
discrepancy in mass. The mass spectrometry data are reported in the appendices.
Table 2. Mass spectrometry verification of correct protein expression and cleavage at the correct site. See
appendix for the mass spectrometry spectra.
Protein

Expected Mass

Actual Mass

Difference

hC2 WT-trx fusion

35,859 Da

35,724 Da

135 Da

hC2 Arg2320Ser-trx fusion

35,790 Da

35,733 Da

57 Da

hC2 Arg2320Thr-trx fusion

35,804 Da

35,668 Da

136 Da

hC2 WT rEK cleaved

18,801 Da

18,798 Da

3 Da

hC2 Arg2320Ser rEK cleaved

18,731 Da

18,731 Da

0 Da

hC2 Arg2320Thr rEK cleaved

18,745 Da

18,741 Da

4 Da
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Affinity Pull-Down Assays
To evaluate proper folding of the mutant proteins, pull-down assays were utilized. The
antibodies were immobilized on TALON resin before incubation of the hC2 mutants.
Binding of the mutant hC2 proteins to the antibodies was assessed by the presence of both
the antibody and hC2 mutant in the elution lanes. The pull-down assays showed both G99
FAB and hC2 mutants in the elution lanes, indicating that all the mutants bound the
nonclassical G99 F AB (Figure 19A/C/E). This suggests proper folding of the mutants.
However, the hC2 Arg2320Ser mutant was unable to bind 3E6 F AB, indicated by the lack
of a 3E6 F AB band in the elution lanes (Figure 19B). This implies that the serine residue
caused a significant unfavorable electrostatic change for the binding of 3E6. Classical 3E6
was able to bind both hC2 Arg2215Ala and hC2 Arg2320Thr mutants (Figure 19D/F).
Though, the 3E6 FAB bands in the elution lanes appear to be less intense compared to the
hC2 bands. These mutations likely attenuated the electrostatic interactions between the
hC2 classical epitope in the mutants and 3E6 FAB due to removal of the positive charge
provided by arginine. Lastly, the Arg2320Ser mutant was not able to not bind 3E6 F AB
while the other mutants were able to likely because it caused the most significant
electrostatic change.
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Figure 19. Affinity pulldown assay results of hC2 mutants with either G99 F AB or 3E6 FAB. The hC2
mutants were immobilized on TALON resin and washed several times with storage buffer to rinse nonbound hC2. Antibodies were then flowed through the column and was also washed several times with
storage buffer. Flow through (FT) and the last wash steps were visualized on SDS-PAGE to verify nonbound proteins were washed out of the column. Elution steps 1 and 2 (first and second 10 mL of elution,
respectively) were visualized to determine antibody binding of the hC2 mutants. Presence of both antibody
and hC2 mutant bands in the elution lanes (highlighted) indicated antibody binding and proper folding of
hC2 mutants. The molecular weights of the mutants were approximately 35.8 kDa and the molecular
weights of the antibodies were approximately 25 kDa. (A) Pulldown assay of hC2 R2320S with G99
FAB indicated antibody binding and proper folding. (B) Pulldown assay of hC2 R2320S with 3E6 F AB
indicated no antibody binding. (C) Pulldown assay of hC2 R2215A with G99 F AB indicated antibody
binding and proper folding. (D) Pulldown assay of hC2 R2215A with 3E6 F AB indicated antibody
binding and proper folding. (E) Pulldown assay of hC2 R2320T with G99 F AB indicated antibody
binding and proper folding. (F) Pulldown assay of hC2 R2320T with 3E6 F AB indicated antibody
binding and proper folding.
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Intrinsic Fluorescence
Intrinsic fluorescence revealed the tertiary stability of the mutants relative to WT hC2 by
monitoring the fluorescence emission of tryptophan residues following excitement at 280
nm during chemical denaturation. As buried tryptophan residues are exposed to solvent,
water serves as an efficient quencher of tryptophan fluorescence. Gibbs free energy
(∆GH20) of unfolding can be calculated from these denaturation curves (Walter et al. 2010).
As predicted, the emission intensity at 335 nm decreased during the denaturation of WT
hC2, indicative of protein unfolding (Figure 20; Munishkina and Fink 2007). In addition,
an increase in fluorescence intensity was observed at around 355 nm due to the increase in
solvent-accessible tryptophan (Munishkina and Fink 2007).
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Figure 20. Intrinsic fluorescence of WT hC2. (A) Denaturation of WT hC2 with increased concentrations
of guanidine-HCl showed a decrease in fluorescence around 335 nm indicative of fluorescence quenching
from the exposure of buried tryptophan residues to solvent during unfolding. (B) Intensities at 324 nm were
graphed with respect to increasing guanidine-HCl concentrations. (C) The most linear region of the
denaturation curve was used to find the ∆GH2O of unfolding.
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Interestingly, the denaturation patterns of the hC2 Arg2320Ser mutant did not resemble
that of WT hC2. From 0 to 1.36 M guanidine-HCl, the intensity trend was inconsistent,
with decreasing intensity from 0 to 0.3 M and increasing in intensity from 0.30 to 1.36 M
guanidine-HCl (Figure 21). This is possibly due to conformational changes that are
quenching the fluorescence of a particular tryptophan residue. The thermodynamic
calculations indicated that the Arg2320Ser mutant was slightly less stable than WT hC2,
with ∆GH20 values of 18.5 kJ/mol and 20.8 kJ/mol, respectively. The 2.3 kJ/mol difference
may not be significant and they may have similar tertiary stability.
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Figure 21. Intrinsic fluorescence of hC2 Arg2320Ser mutant. (A) Denaturation of hC2Arg2320Ser
with increased concentrations of guanidine-HCl showed a general decrease in fluorescence indicative of
fluorescence quenching from the exposure of buried tryptophan residues to solvent during unfolding.
However, fluorescence of the mutant from 0 M to 1.11 M guanidine-HCl conditions showed erratic
intensity curves. (B) Intensities at 345 nm were graphed with respect to increasing guanidine-HCl
concentrations. (C) The most linear region of the denaturation curve was used to find the ∆GH2O of
unfolding.
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Enzyme-Linked Immunosorbent Assays (ELISAs)
ELISAs were employed to assess PS phospholipid binding. A composition of the
phospholipids, 25% phosphatidylserine (PS) and 75% phosphatidylcholine (PC), that
mimicked the activated platelet membranes was initially immobilized to the walls of
hydrophobic 96-well plates and incubated with wild type (WT) hC2 and our hC2 mutants
Arg2320Thr, Arg2215Ala, and Arg2320Ser. Each assay was performed in triplicate. Every
hC2 mutation studied had significantly attenuated phospholipid binding, presumably due
to the loss of the positive charge of arginine. Dissociation constants (KD) for hC2 WT and
Arg2320Thr binding 25% PS/75% PC were 1600 nM and 9100 nM, respectively, in 0 mM
NaCl conditions (Figure 22A). Human C2 Arg2215Ala and Arg2320Ser had binding
affinities of 2400 nM (Figure 22B) and 4.8x1020 nM (Figure 22C), respectively which
indicates these mutations inhibited binding compared to wild type. However, the large K D
for the Arg2320Ser mutant may have been inaccurately calculated due to the unsaturated
PS-binding curve and can be interpreted as having no PS-binding characteristics.

Interestingly, NaCl inhibited WT hC2 binding to 25% PS/75% PC with K D’s of 1300 nM,
1300 nM, 4400 nM, and 5600 nM for 0 mM, 20 mM, 85 mM, and 150 mM concentrations
of NaCl, respectively (Figure 22D). The dissociation constants between the 0 mM and 20
mM NaCl conditions were not significantly different. However, at 85 mM NaCl, the salt
significantly inhibited C2 phospholipid binding. These results concur with the binding
studies performed by Novakovic et al. in 2011, indicating that NaCl competes with the
basic residues within the fVIII C2 domain for negatively charged PS binding.
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Figure 22. ELISA results of the hC2 mutants binding phospholipids compared to wild type hC2. The
binding affinities of hC2 Arg2320Thr (A), Arg2215Ala (B), and Arg2320Ser (C) to phospholipids
were lower than that of wild type hC2. (A) ELISA of Arg2320Thr vs WT hC2 binding to 25%
phosphatidylserine (PS)/75% phosphatidylcholine (PC) in 0 mM NaCl conditions. (B) ELISA of
Arg2215Ala vs WT hC2 binding to 25% PS/75% PC in 0 mM NaCl conditions. (C) ELISA of
Arg2320Ser vs WT hC2 binding to 25% PS/75% PC in 0 mM NaCl conditions. (D) ELISA of
WT hC2 binding to 25% PS/75% PC with varying amounts of NaCl. Increasing concentrations of
NaCl inhibited hC2 binding.
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Crystal Structure of Porcine C2 Interacting with O-Phospho-L-Serine
An X-ray crystal structure of pC2 soaked with the headgroup of phosphatidylserine, Ophospho-L-serine (OPLS), was determined to a resolution of 1.4 Å to identify which
underlying basic residues behind the hydrophobic beta hairpin loops interact with the
negatively charged headgroup of phosphatidylserine (Table 3). The three-dimensional
model of pC2 was initially created by molecular replacement in Phenix.MR using a
previously solved structure of pC2 (PDB ID: 4MO3; Brison et al. in 2015), which
determines the phase of the X-ray diffraction data. Several iterations of manual modeling
within the program, Coot, and automatic refinement in Phenix.refine resulted in a final
pC2 crystal structure with model refinement statistics of R factor (Rwork) and Rfree of 0.1522
and 0.1791, respectively. The R values of OPLS-soaked pC2 structure indicated that the
model fits the diffraction data with high quality due to the values being below 0.2 (Brunger
1992). The Rwork value was lower than that of R free, which indicated non-biased model
fitting into the X-ray diffraction data.
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Table 3. X-Ray Data and Refinement Statistics of the pC2 OPLS structure.
X-Ray Data Statistics

Wavelength
Resolution Range
Space Group

1.00 Å

31.322 Å - 1.401 Å
Orthorhombic I 2 2 2
a = 48.99 Å b = 68.20 Å c = 105.78
Unit Cell
Å α = 90 β = 90 γ = 90
Total Unique Reflections 35,055
13.4 (12.2)
Redundancy
99.7 (99.9) %
Completeness
45.1 (8.04)
I/sigma(I)
0.019 (0.121)
Rpim
Model Refinement Statistics Rfactor (Rwork)
0.1522
Rfree
0.1791
Number of atoms
Protein Atoms
1388
Water Molecules
249
Protein Residues
157
Ligand
1 (OPLS)
RMS Bond Length
0.007 Å
Restraints
RMS Angles Angle
1.283
Restraints
Ramachandran Favored 95.1%
Ramachandran Outliers 1.10%
Rotamer Outliers
0.00%
C-beta Outliers
0
Clashscore
6.21
Overall Score
1.68
23.68 Å 2
Average B-factor
Protein
35.94 Å 2
Solvent
90.78 Å 2
Ligand

59

Figure 23. Manual molecular modeling and refinement of OPLS within the pC2/OPLS crystal structure
using Coot. Blue density shows density that was accounted for during automatic refinement in Phenix. Red
stars respresent individual water molecules. (A) Molecular modeling in the program, Coot, showed positive
density (green) that was unaccounted for in the electron density map. (B) OPLS and a water molecule were
manually added within the program to fit into this positive density. (C) Further refinement using the
software, Phenix, showed an acceptable fit of OPLS.
The purpose of this crystal structure was to investigate which of the basic residues
underlying the hydrophobic beta hairpin loops interact favorably with the negatively
charged headgroup of phosphatidylserine. Modeling of OPLS placement was near
Arg2320, because of the presence of a positive density within the electron density map
(Figure 23). In this structure, we found that Arg2320 was the positive residue that directly
interacted with the negatively charged OPLS, with a distance of 3.5 Å (Figure 24).
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Figure 24. A 1.4 Å crystal structure of pC2 bound to O-phospho-L-serine (OPLS). In cyan is the
Arg2320 residue that interacts with the OPLS (green), with a distance of 3.5 Å. The beta hairpin loops
(gray) are embedded into the hydrophobic membrane (represented by the dashed line and gray-shaded area).
A ring of basic residues (blue) possibly interact with negatively charged phospholipid headgroups during
activated platelet membrane binding, but Arg2320 is likely the main contributor to phosphatidylserine
membrane binding.
The placement of OPLS was in close proximity to the solvent-exposed hydrophobic betahairpin loops hypothesized to be embedded within lipid membranes during binding (Pratt,
et al 1999; Gilbert et al. 2002). This provided structural evidence to support our ‘new’
classical epitope membrane binding model compared to the old model suggested in
previous studies by other labs (Pratt, et al 1999; Stoilova-McPhie et al. 2002) because the
old model appears to have OPLS floating well above the platelet membrane (Figure 25).
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Figure 25. The ternary complex of fVIII/3E6 F AB/G99 FAB overlayed with the OPLS (red)/pC2
crystal structure to demonstrate the (A) new versus (B) old membrane binding models of C2 (PDB ID
4KI5; Walter et al. 2013).
In addition, it is possible that Arg2215 has favorable electrostatic interactions with the
negatively charged phosphate group of OPLS, provided that this Arg2215-containing loop
has high flexibility. A coulombic surface coloring showed the region of OPLS binding
within pC2 is primarily positively charged (Figure 26). Our binding model revealed that
Arg2209, Arg2215, Lys2183, Arg2220, Arg2222, Lys2249, and Arg2320 in pC2 are likely
the basic underlying residues that form salt bridges with the exposed negatively charged
phospholipids on the surface of activated platelet membranes, with Arg2320 being the
main contributor to the direct interaction between OPLS and C2 (Figure 24).
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Figure 26. Coulombic surface coloring (generated in Chimera) of (A) pC2 domain of fVIII in complex
with OPLS and (B) a zoomed-in image of the binding interface. The predominantly positively charged
(blue) binding region of pC2 interacts favorably with the oppositely charged OPLS (green molecule).
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Discussion

FVIII binds to PS-containing membranes primarily with its C2 domain. Within the C2
domain, the two hydrophobic beta hairpin loops penetrate the lipid layer of platelet
membranes. This observation is supported by several different structural and functional
studies from other labs (Pratt et al. 1999; Gilbert et al. 2002; Shen et al. 2008; Madsen et
al. 2015). Several basic residues underlying the hydrophobic beta hairpin loops are
hypothesized to form salt bridges with the negatively charged headgroups of PS on the
surface of activated platelet membranes. However, the specific basic residues that form
these interactions are currently not well defined.

Our research proposes a binding model that is distinct from the older binding model
proposed by Pratt et al. 1999 and other labs (such as Stoilova-McPhie et al. 2002) at the
non-classical epitope face. Previous studies performed in our lab have provided evidence
of the new model at the classical epitope face of C2. Mainly, the C2-bound
phosphatidylserine (PS) was able to bind the non-classical G99 mAb, but not the classical
3E6 mAb, revealing that PS blocks 3E6 mAb binding because they bind at the same C2
epitope (Brison et al. 2015). This indicates PS binds at the classical epitope face, and not
the non-classical epitope face. This sparked our interest in elucidating the atomic-level
details of C2 bound to OPLS for the purpose of providing structural evidence to identify
which underlying basic residue directly interacts with the negatively charged phospholipid,
PS.
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Through this pC2-OPLS crystal structure, we found that the conserved Arg2320 residue
is the main basic underlying residue that forms a salt bridge with PS, with a distance of 3.5
Å (Figure 24). This finding supports our new model in which the binding of
phosphatidylserine-containing membranes occurs at the Arg2320-centered classical
epitope face (Figure 22). In support of this Arg2320-OPLS interaction, molecular
membrane binding simulations of the C2 domain completed by Madsen et al. in 2015
revealed that basic residues within C2 interact with the phosphate or carboxyl groups of
PS lipids transiently and in a nonspecific manner, except for the two residues: Arg2220
and Arg2320. They found that these two residues can interact directly with the acidic
headgroup of PS lipids. These two direct interactions, however, are mutually exclusive. For
the orientation of C2 to form direct interactions between Arg2320 and PS, this direct
interaction cannot occur for Arg2220. The differences between the old model centered on
Arg2220 and the new C2 membrane binding model centered on Arg2320 exhibit this
precise difference. Furthermore, they employed the same membrane binding simulation
study on the C1 domain and discovered that Arg2163, the residue corresponding to the
same location as Arg2320 within C2, was able to achieve a tight interaction with PS
(Madsen et al. 2015). The equivalent residue of Arg2220 in C2 is Ser2063 in C1, indicating
that the Arg2320 interaction may be more robust since it is conserved between both the
C1 and C2 domains.

In support of the finding that Arg2320 is a central residue involved in PS membrane
binding, the ELISA binding studies showed that the mutations at this residue, Arg2320Ser
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and Arg2320Thr, inhibited phospholipid binding. This indicated the importance of the
basic arginine at this residue location since the positive charge is lost with the serine and
threonine mutations. In accordance with this, Arg2215Ala also caused a loss in C2
phospholipid binding activity. In the new binding model, Arg2215 appeared to be docked
within the hydrophobic layer of the lipid membrane based on its proximity to the
hydrophobic beta hairpin loops, which generated an interest in removing this positive
charge to probe whether this increases C2 phospholipid binding activity. However, our
data showed that Arg2215Ala attenuated binding to phospholipids. This result indicates
that the basic Arg2215 residue also plays an important role in forming a salt bridge with
phospholipid membranes. We now hypothesize that Arg2215 may form a favorable
electrostatic interaction with the negatively charged phosphate group within OPLS, given
that this Arg2215-containing loop is highly flexible.

From the pC2-OPLS crystal structure we also showed that there was no major
conformation change upon OPLS binding. The difference in the pC2 and pC2-OPLS
crystal structures were minimal, with an RMSD value of 0.810 Å, calculated in PyMol when
outliers were not rejected (Figure 27). The main differences between the structures were
in the highly dynamic regions of the beta hairpin loops, N-terminal, and C-terminal.
Omission of these areas reduced the RMSD value to 0.532 Å (when calculated with
residues 2173-2195, 2202-2249, and 2255-2329 and no outlier rejection).
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Figure 27. Superposition of the pC2/OPLS crystal structure (pink) and the previously solved pC2
structure (cyan) (PDB ID 4MO3; Brison et al. 2015), provided an RMSD of 0.810 Å. The RMSD
value with the omission of the dynamic regions of the beta hairpin loops, N-terminal, and C-terminal is
0.532 Å.

A caveat to our studies is that the methods employed only probed membrane binding of
the isolated C2 domain, and not of full-length fVIIIa. The C2 domain within full length
fVIIIa is structurally near the C1 domain. The C1 domain has also been shown to
contribute to binding membranes (Meems et al. 2009). It is possible that the C1 domain
may play a role in orienting the C2 domain during membrane anchoring (Lu et al. 2011).
If this is the case, the new model supports this idea more so than the old model.
Superposition of the pC2-OPLS crystal structure to the human full length fVIII structure
(Shen et al. 2008) show that the classical epitope face of C2 (which includes Arg2320 and
OPLS) faces the C1 domain, whereas the non-classical epitope face does not (Figure 28).
The yellow residues in the back of the image within the C2 domain are the residues
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involved in the old membrane binding model, which shows that the old binding model
would cause C2 to tilt away from the C1 domain during membrane binding, instead of
towards it in the new binding model. Future binding studies should include ELISAs
performed with a C1-C2 construct. Studies should also include ELISAs with C2 mutants
that have mutations in the basic residues involved in the old membrane model such as
Lys2227 and Arg2220 to probe whether they attenuate C2 binding and thus, determine the
importance of these residues for C2 membrane binding.

Figure 28. The pC2/OPLS crystal structure superimposed with a structure of human full length fVIII
(PDB ID 2R7E; Shen et al. 2008). The green OPLS and Arg2320 faces the C1 domain while the
yellow residues involved in the ‘old’ phospholipid binding model do not. This further supports our new
binding model and coincides with the idea that the C1 domain likely orients the C2 domain during
membrane binding.
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The pull-down assays and intrinsic fluorescence studies validated our ELISAs by providing
information about whether the proteins were folded and their structural stability,
respectively. All the hC2 mutants were able to bind to the nonclassical G99 F AB, which
informed us that our hC2 mutant proteins were likely folded properly. The pull-down
assays also showed that the Arg2320Ser mutation disrupted 3E6 binding, which further
supports our hypothesis that hC2 binds membranes at the same site as 3E6, at the classical
epitope. It is also possible that the classical epitope face of C2 was not properly folded.
However, this is unlikely because of the similar protein stability between the Arg2320Ser
mutant and wild type C2. Intrinsic fluorescence revealed that the Arg2320Ser mutation
also decreased protein stability, but only by approximately 11%. This finding, along with
the results from the pull-down assays, suggest that the decreased membrane binding of the
arginine mutants determined by the ELISAs were not due to improper folding of the
mutants. They were most likely due to the removal of the positive charge by mutating the
arginine to residues that have no charge.

Interestingly, we also discovered that NaCl inhibited C2 phospholipid binding, even at the
physiological salt concentration, 150 mM NaCl (Figure 22D). This finding has also been
supported by a study from a different lab (Novakovic et al. 2011). The observed
attenuation of phospholipid binding is likely due to NaCl competing with the basic residues
of C2 for the negatively charged phosphatidylserine during binding. In the presence of 80
mM NaCl, the KD increased by approximately 70% compared to binding with no salt

69

present. This leads to the conclusion that in vivo, C2 membrane binding is dependent on
other factors, such as the proximity of the C1 domain. Thus, future lipid binding needs to
be further investigated with intact fVIII to complement our isolated C2 domain studies. It
has been found that the C2 domain binds membranes with a 40-fold lower affinity than
intact fVIII (Novakovic et al. 2011), further indicating that fVIII membrane binding is
complex and in order to understand the full mechanism, supplementary binding studies
must be done. This observation, however, does not undermine our isolated C2 domain
binding research as it still reveals the important basic residues within C2 that are involved
in PS-containing membrane binding. Gilbert et al. in 2002 were unable to express an intact
B-domain-deleted fVIII Arg2320Ala mutant. Because we were able to isolate the Arg2320
mutants in the C2 domain, our studies showed the importance of this residue during PSmembrane binding. This same group, nonetheless, was able to investigate an intact Bdomain-deleted fVIII Arg2215Ala mutant. The clotting activity of this mutant was similar
to wild type revealed by an activated partial thromboplastin time assay (Gilbert et al. 2002).
In contrast, our hC2 Arg2215Ala mutant was unable to bind PS compared to wild type
hC2. This further suggests that the full-length fVIII lipid binding mechanism is more
complex than that of isolated C2.

Although this study was not all-encompassing, we have provided useful structural
information about the phospholipid membrane binding mechanism of the isolated C2
domain within fVIII. Mainly, the orientation of the C2 domain during membrane binding
is likely centered on Arg2320Ser, and occurs at the classical epitope face. Specific
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interactions between activated platelet membranes include favorable interactions of the
two hydrophobic beta hairpin loops (Met2199-Phe2200 and Leu2251-Lue2252) with the
hydrophobic lipid bilayer of membranes. The underlying basic residues Arg2209, Arg2215,
Lys2183, Arg2220, Arg2222, Lys2249, and Arg2320 in pC2 likely form nonspecific salt
bridges with negatively charged phosphate or carboxyl groups of phospholipids on the
surface of activated platelet membranes, with Arg2320 being the main contributor to the
interaction between C2 and OPLS (Figure 24). In the future, other researchers may use
this information to design novel fVIII replacement concentrates that have an increased
activity in phospholipid binding for the improvement in current hemophilia A
therapeutics.
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Appendix

Appendix Figure 1. DNA sequencing results from Nevada Genomics. Highlighted yellow
are the hC2 or hC1 gene sequences. Highlighted in green or cyan are the correct mutations.
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Appendix Figure 2. Human C2 wild type thioredoxin fusion mass spectrometry results.
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Appendix Figure 3. Human C2 R2320S thioredoxin fusion mass spectrometry results.
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Appendix Figure 4. Human C2 R2320T thioredoxin fusion mass spectrometry results.
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Appendix Figure 5. Human C2 wild type recombinant enterokinase cleaved mass spectrometry results.
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Appendix Figure 6. Human C2 R2320S recombinant enterokinase cleaved mass spectrometry results.
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Appendix Figure 7. Human C2 R2320T recombinant enterokinase cleaved mass spectrometry results.
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